|
|
10911 Technology Place
San Diego, CA 92127 USA
phone:
(858) 217-0300
fax:
(858)217-0301 |
| Symbol |
Private |
| Exchange |
Private |
| Founded |
2003 |
| Employees |
|
|
|
 www.minnowmedical.com |
|
| Research Sector |
Medical Devices & Tech |
|
|
| Summary Description |
| Radio frequency-based catheter technology for the treatment of atherosclerosis |
|
| Management |
| Thomas A. Steinke, CEO; Michael D. Perry, Vice President Engineering; Corbett W. Stone, Chief Technology Officer; Michael F. Hoey, PhD, Scientific Officer; Sharon A. Riddle, Vice President Market Development; John P. Schmid, Chief Financial Officer |
|
|
|
|
| Keywords |
| atherosclerotic, atherosclerosis, disease, artery, catheter, cardiovascular, stents, novel, radio, frequency, advamed, j2008 |
|
|
|
|
Description |
| Minnow Medical, Inc. headquartered in San Diego, California develops products to treat artery disease which can occur throughout the body, including the heart, neck and head, and legs.
|
|
| Products / Services |
The Minnow Medical system consists of a disposable catheter through which a separate console generates electromagnetic energy to characterize, measure and immediately shrink atherosclerotic plaques without damaging adjacent healthy tissue.
|
|
| Technology / Differentiation |
| Minnow Medical's artery disease treatment affects the structure and function of the plaque in the artery which causes an immediate reduction in plaque volume, a minimization of artery recoil and a sustained, enlarged arterial inner diameter. This gentle treatment occurs within seconds and there is an immediate increase in blood flow. A pro-healing process continues after treatment as the body naturally recovers. The treatment is fast, result is immediate, no embolic debris is generated, and no implant (stent) is left behind. Unlike, other current technologies used in the treatment of PAD, the Minnow technology does not cause stretching, tearing, burning, freezing or cutting of the artery to reduce the volume of atherosclerotic disease. |
|
| Market / Customers |
The intended use of Minnow Medical's first product, the GRT Peripheral Catheter System is for the treatment of Peripheral Artery Disease (PAD). It is estimated that 12 million Americans have PAD which can be debilitating, and in its worse case, Critical Limb Ischemia, cause limb loss for over 150,000 Americans per year. Minnow plans on leveraging its patented technology to other parts of the cardiovascular system. Atherosclerosis is a systemic disease, and disease in the legs is almost always linked to disease in other vascular beds; such as the Coronary, Carotid, and Cerebral vasculature.
|
|
| Competitors / Substitutes / Alternatives |
Current catheter-based treatments for artery disease; angioplasty, laser, cryoplasty, and atherectomy have limited efficacy due to the resulting trauma to the arterial artery. This damage contributes to restenosis (narrowing of the artery) which can lead to artery closure. No other currently used technology is capable of differentiating between healthy and diseased tissue, current medical devices treat all tissue as if it was homogeneous.
The key limitation to all current technologies is that they do not account for the heterogeneous, eccentric plaque distribution evident in 80% of diseased arteries.
|
|
| Strategy |
Minnow is currently in early clinical trials treating Peripheral Artery Disease. In the future, the company plans on leveraging its broadly applicable proprietary technology into the Coronary, Carotid and Cerebral markets including a focus the emerging vulnerable plaque opportunity.
|
|
| Status |
| Minnow is currently in early clinical trials treating Peripheral Artery Disease. In the future, the company plans on leveraging its broadly applicable proprietary technology into the Coronary, Carotid and Cerebral markets including a focus the emerging vulnerable plaque opportunity |
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
